Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,459 signal articles · 145 in last 24h · 154,156 total before filter · latest 1h ago
145last 24h
874last 7d
145● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings107M&A125Regulatory21Product21Analyst17
✕ clear all filtersticker: CVSsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
How Tech Leaders Are Navigating AI’s ROI Problem
WSJ8d agoneutralVIDEO
How Tech Leaders Are Navigating AI’s ROI Problem

At the WSJ Leadership Institute's Technology Council Summit, technology executives from McKinsey, FedEx and CVS Health discuss how they are navigating the rising costs of generative AI and finding real business value.

CVS’s Turnaround Faces Its Next Test
Barrons.com51d agoneutral
CVS’s Turnaround Faces Its Next Test

CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.

FTC Reaches Settlement With CVS Health Over Insulin Prices
Barrons.com72d agoneutral
FTC Reaches Settlement With CVS Health Over Insulin Prices

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.